Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cyclopharm Limited ( (AU:CYC) ) has issued an announcement.
Cyclopharm Limited has entered a new growth phase following the USFDA approval of Technegas™ for lung imaging, which has significantly boosted its sales in the United States. The company achieved a 131% increase in US sales in 2024, with continued momentum into 2025, and has secured key agreements with major healthcare providers, enhancing its market reach. The expansion into the US market is expected to accelerate research into new clinical applications, potentially unlocking a global market opportunity estimated at US$900 million. Additionally, Cyclopharm is strengthening its third-party distribution business, contributing to its revenue diversity and margin resilience.
The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited operates in the healthcare industry, specializing in medical imaging technology. Its primary product, Technegas™, is used for lung imaging and is particularly known for diagnosing Pulmonary Embolism (PE). The company is focused on expanding its market presence, especially in the United States, and is also involved in third-party distribution of radiopharmaceuticals and related equipment.
Average Trading Volume: 99,631
Technical Sentiment Signal: Sell
Current Market Cap: A$134.5M
Learn more about CYC stock on TipRanks’ Stock Analysis page.